Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANSPOR vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
FDA-approved: Treatment of respiratory tract infections, otitis media, skin and skin structure infections, bone infections, genitourinary tract infections caused by susceptible bacteria.,Off-label: Prosthetic joint infections, dental infections, endocarditis prophylaxis.
Perioperative prophylaxis,Respiratory tract infections,Urinary tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Genital infections (e.g., prostatitis, epididymitis),Off-label: Surgical prophylaxis in certain procedures
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (Cr Cl <10 m L/min)
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (Cr Cl <10 m L/min)
Cephalexin is not extensively metabolized; it is primarily excreted unchanged in the urine. Minor hepatic metabolism may occur.
Cefazolin is minimally metabolized; primarily undergoes renal tubular secretion and glomerular filtration. Not significantly metabolized by cytochrome P450 enzymes.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
10–20% bound to serum albumin
80-86% bound to serum albumin
0.13–0.22 L/kg; indicates distribution primarily into extracellular fluid
0.12-0.16 L/kg; primarily in extracellular fluid
Oral: 75–90% (well absorbed); IM: 100%
IM: ~85% (peak levels in 0.5-2 hours); IV: 100%
Cr Cl 10-50 m L/min: 250 mg every 12-24 hours. Cr Cl <10 m L/min: 250 mg every 24-48 hours.
Cr Cl 35-54 m L/min: 1-2 g every 8 hours. Cr Cl 11-34 m L/min: 1-2 g every 12 hours. Cr Cl <10 m L/min: 1-2 g every 24-48 hours. For patients on hemodialysis, administer 1-2 g after each dialysis session.
No specific adjustment recommended; monitor for adverse effects in severe impairment.
No dosage adjustment required for hepatic impairment. Cefazolin is primarily renally eliminated.
12.5-25 mg/kg orally every 6 hours; maximum 50 mg/kg/day.
For children >1 month: 25-100 mg/kg/day IV divided every 6-8 hours. For severe infections: up to 100 mg/kg/day IV divided every 6-8 hours. Maximum dose: 6 g/day.
Start at lower end of dosing range; monitor renal function and adjust based on Cr Cl.
Adjust dose based on renal function. Calculate Cr Cl and follow renal adjustment guidelines. No additional geriatric-specific modifications beyond renal consideration.
No FDA boxed warning exists for cephalexin.
None
Hypersensitivity reactions including anaphylaxis.,Clostridioides difficile-associated diarrhea (CDAD).,Dosage adjustment required in renal impairment.,Seizures with high doses or renal failure.,Potential for superinfection with prolonged use.
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams; caution in penicillin-allergic patients,Acute generalized exanthematous pustulosis (AGEP),Clostridioides difficile-associated diarrhea (CDAD),Seizures at high doses or in renal impairment,Nephrotoxicity (especially with aminoglycosides or loop diuretics),Hemolytic anemia (rare),Interference with glucose and protein tests,Use in renal impairment: dose adjustment required,Pregnancy category B: use only if clearly needed,Geriatric use: increased risk of adverse effects
Known hypersensitivity to cephalosporins or penicillins (cross-sensitivity).,Previous immediate hypersensitivity reaction to penicillins.
Hypersensitivity to cefazolin or any cephalosporin,Severe immediate hypersensitivity (e.g., anaphylaxis) to penicillins or other beta-lactams
Iron-fortified infant formula and iron supplements may reduce absorption; take at least 2 hours apart. No other significant food interactions. Avoid alcohol.
No specific food interactions. Avoid alcohol during therapy and for 72 hours post-treatment due to risk of disulfiram-like reaction (cefazolin has a methylthiotetrazole side chain). Patients with diabetes should account for dextrose content (5 g/100 m L) in their carbohydrate intake.
Cefradine (ANSPOR) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. No evidence of teratogenicity; however, caution is advised. First trimester: no known risk; second and third trimesters: no known fetal adverse effects.
Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in first trimester; use only if clearly needed.
Cefradine is excreted into human breast milk in low concentrations. M/P ratio is approximately 0.12–0.20. Considered compatible with breastfeeding by the American Academy of Pediatrics; however, monitor infant for potential diarrhea or allergic reaction.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2-0.5). Considered compatible with breastfeeding; monitor for potential gastrointestinal effects in the infant.
Increased renal clearance during pregnancy may lower serum concentrations of cefradine. Standard dosing (250–500 mg every 6 hours) is generally adequate; however, for severe infections, consider higher doses or more frequent administration based on clinical response. No specific dose adjustment is routinely recommended, but monitoring therapeutic efficacy is advised.
Increased glomerular filtration rate during pregnancy may require higher doses or more frequent dosing to achieve therapeutic concentrations; specific dose adjustment not established; monitor clinical response.
ANSPOR (cefdinir) is a third-generation oral cephalosporin with activity against Gram-positive and Gram-negative bacteria. It is stable in the presence of some beta-lactamases. Dose adjustment required for Cr Cl <30 m L/min. Avoid use in patients with immediate hypersensitivity to penicillins due to cross-reactivity (approx 10%). Administer with iron supplements or iron-fortified infant formula at least 2 hours apart to reduce chelation. Suspension should be refrigerated and discarded after 10 days.
For surgical prophylaxis, administer within 60 minutes before incision. Use extended infusion (over 1-2 hours) for critically ill patients to optimize pharmacokinetic/pharmacodynamic target attainment. Monitor renal function given cefazolin excretion; adjust dose for Cr Cl <55 m L/min. Avoid in patients with immediate-type hypersensitivity to penicillins (10% cross-reactivity risk). In obese patients (BMI ≥40 kg/m²), consider doubling the standard dose (2 g IV) for adequate tissue penetration.
Take exactly as prescribed, even if you feel better.,Complete the full course of therapy.,If using suspension, shake well before each dose. Refrigerate and discard after 10 days.,Avoid alcohol while taking this medication.,Notify your doctor if you experience diarrhea, rash, or signs of allergic reaction.,Take iron supplements or iron-fortified infant formula at least 2 hours apart from ANSPOR.
Complete the full course of antibiotics as prescribed, even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling of face or throat) to your healthcare provider immediately.,If you are diabetic, note that each 1% dextrose solution provides 3.4 kcal/g; monitor blood glucose levels closely.,The medication is given intravenously; ensure the IV site is clean and free from redness, swelling, or pain.,Avoid alcohol during treatment and for at least 72 hours after the last dose to prevent disulfiram-like reactions (flushing, nausea, vomiting).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANSPOR vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ANSPOR is a Cephalosporin Antibiotic that works by Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANSPOR and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANSPOR is: 250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.. The standard adult dose of ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is: For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANSPOR and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANSPOR is classified as Category C. Cefradine (ANSPOR) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. N. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.